Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 24, Issue SUPPL.6, 2013, Pages

  Peccatori, F A ^a   Azim, Jr ^b   Orecchia, R ^a   Hoekstra, H J ^c   Pavlidis, N ^d   Kesic, V ^e   Pentheroudakis, G ^d  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b JULES BORDET INSTITUTE   (Belgium)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d UNIVERSITY OF IOANNINA   (Greece)

^e UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CARBOPLATIN; CISPLATIN; CYTARABINE; DOXORUBICIN; IMATINIB; PACLITAXEL; PLATINUM DERIVATIVE; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVOR; CHILDHOOD CANCER; CHRONIC MYELOID LEUKEMIA; DRUG CONTRAINDICATION; DRUG SAFETY; FEMALE FERTILITY; FERTILITY PRESERVATION; FETAL WELL BEING; FETUS MALFORMATION; FETUS MONITORING; FIRST TRIMESTER PREGNANCY; GERM CELL TUMOR; GESTATIONAL AGE; HUMAN; INTRAUTERINE GROWTH RETARDATION; LEUKEMIA; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MASTECTOMY; MELANOMA; MENTAL DEFICIENCY; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSTETRIC PROCEDURE; OVARY CANCER; OVARY CARCINOMA; OVARY TUMOR; PARTIAL MASTECTOMY; PELVIS RADIOGRAPHY; PREGNANCY; PREGNANCY OUTCOME; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SENTINEL LYMPH NODE BIOPSY; SOFT TISSUE SARCOMA; SYSTEMIC THERAPY; TREATMENT INDICATION; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; EUROPE; FEMALE; FERTILITY; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; LEUKEMIA; LYMPHOMA, NON-HODGKIN; MASTECTOMY, SEGMENTAL; MELANOMA; NEOPLASM STAGING; NEOPLASMS; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; RISK ASSESSMENT; UTERINE CERVICAL NEOPLASMS;

EID: 84885341204     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt199     Document Type: Article

References (73)

1. Matthews TJ, Hamilton BE. Delayed childbearing: more women are having their first child later in life. NCHS Data Brief 2009; 1-8.
2. Pentheroudakis G, Pavlidis N. Cancer and pregnancy: poena magna, not anymore. Eur J Cancer 2006; 42: 126-140.
3. Stensheim H, Møller B, van Dijk T, Fosså SD. Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. J Clin Oncol 2009; 27: 45-51.
4. Mieog JS, van der Hage JA, van de Velde CJ. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg 2007; 94: 1189-1200.
5. Amant F, Deckers S, Van Calsteren K et al. Breast cancer in pregnancy: Recommendations of an international consensus meeting. Eur J Cancer 2010; 46: 3158-3168.
6. Azim HA Jr, Santoro L, Russell-Edu W et al. Prognosis of pregnancy-associated breast cancer: a meta-analysis of 30 studies. Cancer Treat Rev 2012; 38: 834-842.
7. Wang PI, Chong ST, Kielar AZ et al. Imaging of pregnant and lactating patients: part 2, evidence-based review and recommendations. AJR Am J Roentgenol 2012; 198: 785-792.
8. Han SN, Lotgerink A, Gziri MM et al. Physiologic variations of serum tumor markers in gynecological malignancies during pregnancy: a systematic review. BMC Med 2012; 10: 86.
9. Van Calsteren K, Heyns L, De Smet F et al. Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J Clin Oncol 2010; 28: 683-689.
10. Cardonick E, Dougherty R, Grana G et al. Breast cancer during pregnancy: maternal and fetal outcomes. Cancer J 2010; 16: 76-82.
11. Loibl S, Han SN, von Minckwitz G et al. Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol 2012; 13: 887-896.
12. Amant F, Van Calsteren K, Halaska MJ et al. Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. Lancet Oncol 2012; 13: 256-264.
13. Litton JK, Hodge S, Mattair D et al. Outcomes of children exposed to chemotherapy in utero for breast cancer. J Clin Oncol 2011; 29 Abstr # 1099.
14. Perret-Court A, Fernandez C, Monestier S et al. [Placental metastasis of melanoma: a new case and literature review]. Ann Pathol 2010; 30: 143-146.
15. Gentilini O, Cremonesi M, Trifirò G et al. Safety of sentinel node biopsy in pregnant patients with breast cancer. Ann Oncol 2004; 15: 1348-1351.
16. Kal HB, Struikmans H. Radiotherapy during pregnancy: fact and fiction. Lancet Oncol 2005; 6: 328-333.
17. Spanheimer PM, Graham MM, Sugg SL et al. Measurement of uterine radiation exposure from lymphoscintigraphy indicates safety of sentinel lymph node biopsy during pregnancy. Ann Surg Oncol 2009; 16: 1143-1147.
18. Gentilini O, Cremonesi M, Toesca A et al. Sentinel lymph node biopsy in pregnant patients with breast cancer. Eur J Nucl Med Mol Imaging 2010; 37: 78-83.
19. Cimmino VM, Brown AC, Szocik JF et al. Allergic reactions to isosulfan blue during sentinel node biopsy-a common event. Surgery 2001; 130: 439-442.
20. Chen Z, King W, Pearcey R et al. The relationship between waiting time for radiotherapy and clinical outcomes: a systematic review of the literature. Radiother Oncol 2008; 87: 3-16.
21. Balleyguier C, Fournet C, Ben Hassen W et al. Management of cervical cancer detected during pregnancy: role of magnetic resonance imaging. Clin Imaging 2013; 37: 70-76.
22. Shepherd JH. Cervical cancer. Best Pract Res Clin Obstet Gynaecol 2012; 26: 293-309.
23. Morice P, Uzan C, Gouy S et al. Gynaecological cancers in pregnancy. Lancet 2012; 379: 558-569.
24. Fruscio R, Villa A, Chiari S et al. Delivery delay with neoadjuvant chemotherapy for cervical cancer patients during pregnancy: a series of nine cases and literature review. Gynecol Oncol 2012; 126: 192-197.
25. Amant F, Van Calsteren K, Halaska MJ et al. Gynecologic cancers in pregnancy: guidelines of an international consensus meeting. Int J Gynecol Cancer 2009; 19 (Suppl 1): S1-12.
26. Azim HA Jr, Peccatori FA, Pavlidis N. Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: solid tumors. Cancer Treat Rev 2010; 36: 101-109.
27. Azim HA Jr, Pavlidis N, Peccatori FA. Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part II: hematological tumors. Cancer Treat Rev 2010; 36: 110-121.
28. Van Calsteren K, Verbesselt R, Ottevanger N et al. Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study. Acta Obstet Gynecol Scand 2010; 89: 1338-1345.
29. Ellis GK, Barlow WE, Gralow JR et al. Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012. J Clin Oncol 2011; 29: 1014-1021.
30. Sparano JA, Wang M, Martino S et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358: 1663-1671.
31. Hahn KM, Johnson PH, Gordon N et al. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer 2006; 107: 1219-1226.
32. Peccatori FA, Azim HA Jr, Scarfone G et al. Weekly epirubicin in the treatment of gestational breast cancer (GBC). Breast Cancer Res Treat 2009; 115: 591-594.
33. Van Calsteren K, Verbesselt R, Van Bree R et al. Substantial variation in transplacental transfer of chemotherapeutic agents in a mouse model. Reprod Sci 2011; 18: 57-63.
34. Zagouri F, Sergentanis TN, Chrysikos D et al. Taxanes for breast cancer during pregnancy: a systematic review. Clin Breast Cancer 2013; 13: 16-23.
35. Cardonick E, Bhat A, Gilmandyar D, Somer R. Maternal and fetal outcomes of taxane chemotherapy in breast and ovarian cancer during pregnancy: case series and review of the literature. Ann Oncol 2012; 23: 3016-3023.
36. Braems G, Denys H, De Wever O et al. Use of tamoxifen before and during pregnancy. Oncologist 2011; 16: 1547-1551.
37. Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res Part B Dev Reprod Toxicol 2009; 86: 328-344.
38. Azim HA Jr, Azim H, Peccatori FA. Treatment of cancer during pregnancy with monoclonal antibodies: a real challenge. Expert Rev Clin Immunol 2010; 6: 821-826.
39. Zagouri F, Sergentanis TN, Chrysikos D et al. Trastuzumab administration during pregnancy: a systematic review and meta-analysis. Breast Cancer Res Treat 2013; 137: 349-357.
40. Brenner B, Avivi I, Lishner M. Haematological cancers in pregnancy. Lancet 2012; 379: 580-587.
41. Pye SM, Cortes J, Ault P et al. The effects of imatinib on pregnancy outcome. Blood 2008; 111: 5505-5508.
42. Hoekstra HJ. Melanoma during pregnancy: therapeutic management and outcome. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 2008; 178: 175-181.
43. Andtbacka RH, Donaldson MR, Bowles TL et al. Sentinel lymph node biopsy for melanoma in pregnant women. Ann Surg Oncol 2013; 20: 689-696.
44. Mir O, Berrada N, Domont J et al. Doxorubicin and ifosfamide for high-grade sarcoma during pregnancy. Cancer Chemother Pharmacol 2012; 69: 357-367.
45. Judson I, Verweij J, Gelderblom H et al. Results of a randomised phase III trial (EORTC 62012) of single agent doxorubicin versus doxorubicin plus ifosfamide as first line chemotherapy for patients with advanced or metastatic soft tissue sarcoma. A survival study by the EORTC soft tissue and bone sarcoma group. Ann Oncol 2012; 23 (Suppl 9): LBA7.
46. Ghaemmaghami F, Abbasi F, Abadi AG. A favorable maternal and neonatal outcome following chemotherapy with etoposide, bleomycin, and cisplatin for management of grade 3 immature teratoma of the ovary. J Gynecol Oncol 2009; 20: 257-259.
47. Cardonick E, Usmani A, Ghaffar S. Perinatal outcomes of a pregnancy complicated by cancer, including neonatal follow-up after in utero exposure to chemotherapy: results of an international registry. Am J Clin Oncol 2010; 33: 221-228.
48. Han JY, Nava-Ocampo AA, Kim TJ et al. Pregnancy outcome after prenatal exposure to bleomycin, etoposide and cisplatin for malignant ovarian germ cell tumors: report of 2 cases. Reprod Toxicol 2005; 19: 557-561.
49. Peterson C, Lester DR, Jr, Sanger W. Burkitt's lymphoma in early pregnancy. J Clin Oncol 2010; 28: e136-138.
50. Bokemeyer C, Beyer J, Metzner B et al. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 1996; 7: 31-34.
51. Kondagunta GV, Bacik J, Donadio A et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 2005; 23: 6549-6555.
52. Azim HA Jr, Peccatori FA, Pavlidis N. Lung cancer in the pregnant woman: to treat or not to treat, that is the question. Lung Cancer 2010; 67: 251-256.
53. Azim HA Jr, Metzger-Filho O, de Azambuja E et al. Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01). Breast Cancer Res Treat 2012; 133: 387-391.
54. Stensheim H, Cvancarova M, Møller B, Fosså SD. Pregnancy after adolescent and adult cancer: a population-based matched cohort study. Int J Cancer 2011; 129: 1225-1236.
55. Langagergaard V, Gislum M, Skriver MV et al. Birth outcome in women with breast cancer. Br J Cancer 2006; 94: 142-146.
56. De Sanctis V, Filippone FR, Alfo M et al. Impact of different treatment approaches on pregnancy outcomes in 99 women treated for Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2012; 84: 755-761.
57. Ives A, Saunders C, Bulsara M, Semmens J. Pregnancy after breast cancer: population based study. BMJ 2007; 334: 194.
58. Kroman N, Jensen MB, Wohlfahrt J, Ejlertsen B. Pregnancy after treatment of breast cancer-a population-based study on behalf of Danish Breast Cancer Cooperative Group. Acta Oncol 2008; 47: 545-549.
59. Azim HA Jr, Santoro L, Pavlidis N et al. Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies. Eur J Cancer 2011; 47: 74-83.
60. Azim HA Jr, Kroman N, Paesmans M et al. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. J Clin Oncol 2013; 31: 73-79.
61. Abusief ME, Missmer SA, Ginsburg ES et al. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer 2010; 116: 791-798.
62. Partridge A, Gelber S, Gelber RD et al. Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Eur J Cancer 2007; 43: 1646-1653.
63. Partridge AH, Ruddy KJ, Gelber S et al. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil Steril 2010; 94: 638-644.
64. Peccatori FA, Pup LD, Salvagno F et al. Fertility Preservation Methods in Breast Cancer. Breast care 2012; 7: 197-202.
65. Badawy A, Elnashar A, El-Ashry M, Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomised study. Fertil Steril 2009; 91: 694-697.
66. Gerber B, von Minckwitz G, Stehle H et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol 2011; 29: 2334-2341.
67. Munster PN, Moore AP, Ismail-Khan R et al. Randomized trial using gonadotropinreleasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol 2012; 30: 533-538.
68. Del Mastro L, Boni L, Michelotti A et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomised trial. JAMA 2011; 306: 269-276.
69. Demeestere I, Brice P, Peccatori FA et al. Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomised trial. J Clin Oncol 2013; 31: 903-909.
70. Oktay K, Buyuk E, Libertella N et al. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 2005; 23: 4347-4353.
71. Oktay K, Hourvitz A, Sahin G et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab 2006; 91: 3885-3890.
72. Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol 2008; 26: 2630-2635.
73. Donnez J, Silber S, Andersen CY et al. Children born after autotransplantation of cryopreserved ovarian tissue. a review of 13 live births. Ann Med 2011; 43: 437-450.